Clinical trials: Arthrosis
Pain, Low Back Pain
An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants
The purpose of this study is to evaluate the efficacy, safety and to explore the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of…
- Conditions
- Pain, Low Back Pain, Back Pain, Osteoarthritis, Knee
- Trial name
- NCT01124604
- Testing
- Tapentadol Hydrochloride
- Where
- 19 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Janssen Pharmaceutical K.K.
Rheumatoid Arthritis
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).
- Trial name
- OSKIRA-X (NCT01242514)
- Testing
- Fostamatinib
- Where
- 308 sites in United States, Argentina and 29 more
- Volunteers
- 1,917 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis.
- Trial name
- NCT01393639
- Testing
- PF-04171327, prednisone
- Where
- 93 sites in United States, Bulgaria and 16 more
- Volunteers
- 323 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.
- Trial name
- NCT01712178
- Testing
- Adalimumab, current formulation, Adalimumab, new formulation
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 100 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Osteoarthritis, Low Back Pain
An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain
The purpose of this study is to evaluate the efficacy and safety of fentanyl among Filipino participants with osteoarthritis (disorder which is seen mostly in older persons in which the joints become painful and stiff) and…
- Trial name
- NCT01795898
- Testing
- Fentanyl
- Where
- Philippines
- Volunteers
- 237 people
- Sponsor
- Janssen Pharmaceutica
Rheumatoid Arthritis
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra in patients with rheumatoid arthritis who have had an inadequate response (or were intolerant to)…
- Trial name
- NCT01579006
- Testing
- Tocilizumab
- Where
- 14 sites in Israel
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis
This non-interventional, retrospective, cross sectional chart review study will evaluate the management of rheumatoid arthritis patients with a biologic in monotherapy.
- Trial name
- NCT01640548
- Where
- 26 sites in United Kingdom
- Volunteers
- 320 people
- Sponsor
- Hoffmann-La Roche
Osteoarthritis of the Knee
A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee
The primary purpose of the study is to evaluate the change from baseline after 4 weeks of topical administration of TV-45070 (4% and 8% ointment) compared with placebo for the relief of symptoms of primary OA affecting a single…
- Trial name
- NCT02068599
- Testing
- TV-45070
- Where
- 42 sites in United States
- Volunteers
- 389 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Osteoarthritis
Mobile Motivational Physical Activity Targeted Intervention
More than 50% of older persons with osteoarthritis (OA) experience disrupted sleep and insomnia symptoms of difficulty falling asleep, awakening during the night, and awakening too early and being unable to fall back to sleep.
- Trial name
- MobMPATI (NCT03160287)
- Testing
- Motivaltional interviews and infrequent motivational text messages
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
This 3-part study evaluated the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis who have an inadequate response to, or were intolerant of methotrexate.
- Trial name
- NCT00988221
- Testing
- Tocilizumab
- Where
- 69 sites in United States, Argentina and 13 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- NURTURE 1 (NCT01350804)
- Testing
- AIN457, Abatacept
- Where
- 117 sites in United States, Brazil and 13 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Knee, Osteoarthritis Knees Both
Astaxanthin for Management of Inflammation in Knee Osteoarthritis
Over 30 million Americans are currently affected by osteoarthritis (OA), with prevalence expected to increase 40% by 2025 as a result of the aging population and obesity epidemic.
- Conditions
- Osteoarthritis, Knee, Osteoarthritis Knees Both, Joint Inflammation
- Trial name
- NCT05138549
- Testing
- Astaxanthin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Prisma Health-Midlands
Psoriatic Arthritis
The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated…
- Trial name
- NCT01818804
- Testing
- n-3PUFA, olive oil
- Where
- 2 sites in Denmark
- Volunteers
- 145 people
- Sponsor
- Aalborg University Hospital
RheumatoId Arthritis
The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study
Comparing the cost-effectiveness and safety of additional low-dose glucocorticoid in treatment strategies for elderly patients with rheumatoid arthritis: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study (GLORIA)
- Trial name
- Gloria (NCT02585258)
- Testing
- Prednisolone
- Where
- 28 sites in Germany, Hungary and 5 more
- Volunteers
- 451 people
- Sponsor
- Amsterdam UMC, location VUmc
Rheumatoid Arthritis, Bone Resorption
Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are characterized by chronic systemic inflammation and share common pathogenic pathways.
- Conditions
- Rheumatoid Arthritis, Bone Resorption, Ankylosing Spondylitis
- Trial name
- NCT01417455
- Where
- Portugal
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Instituto de Medicina Molecular João Lobo Antunes
Rheumatoid Arthritis (RA)
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the…
- Trial name
- NCT03086343
- Testing
- Abatacept, Upadacitinib
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 657 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol as add-on medication to methotrexate over the long term in Japanese RA patients transferred from Study 275-08-001 (NCT00791999), and to…
- Trial name
- NCT00851318
- Testing
- Certolizumab pegol, Methotrexate
- Where
- 8 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
This open-label, single arm, Phase 3b study will evaluate the efficacy of tocilizumab (RoActemra), administered as monotherapy or in combination with methotrexate and/or other DMARDs, in participants with moderate to severe…
- Trial name
- NCT01941940
- Testing
- Tocilizumab, DMARDs
- Where
- 49 sites in Italy
- Volunteers
- 227 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.
This study will evaluate the safety and efficacy of SKI-O-703 compared with placebo, in patients with active rheumatoid arthritis (RA) who have had an inadequate response to conventional synthetic disease-modifying agents.
- Trial name
- NCT04057118
- Testing
- SKI-O-703
- Where
- 40 sites in United States, Czechia and 3 more
- Volunteers
- 163 people
- Sponsor
- Oscotec Inc.
Psoriatic Arthritis
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
- Trial name
- NCT03552276
- Testing
- SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg)
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 281 people
- Sponsor
- Sun Pharmaceutical Industries Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.